A Pharmacovigilance Study of Topical Acne Monotherapy with 0.1% Adapalene, and A Molecular Analytical Review of Adapalene in Evidence-Based Dermatopharmacological Treatment

Acne vulgaris causes cosmetic impairment. User-friendly anti-acne monotherapy with adapalene has activity against the acnepathophysiology, with very minimal adverse effects. Retinoids, like adapalene, are comedolytic and anti-inflammatory. This study wasconducted as a pharmacovigilance study of topical acne monotherapy with 0.1% adapalene, and a molecular analytical review ofadapalene in evidence-based dermatopharmacological treatment. A prospective, open- labelled study was done, on 75 patients, withmild to moderate acne. Patients applied 0.1% adapalene topical monotherapy, once daily in the evening, over affected areas on theface, and left overnight. Efficacy was measured by percentage reduction in non-inflammatory, inflammatory and total lesion countson 0, 15, 30, 60 and 90 days; and severity of lesions was assessed by Investigator’s Global Evaluation Scale and the occurrence ofadverse effects like erythyma, dryness, scaling, burning and pruritus, were assessed by the Local Irritation Scale, among the patientsreceiving the monotherapy. An analytical review of the molecular pharmacology of adapalene in evidence-baseddermatopharmacological treatment was thoroughly performed. The patients showed highly significant reduction in total lesioncounts from baseline. No serious adverse effects were observed; and the observations were statistically non-significant. Themolecular analytical review described significantly effective evidence-based dermatopharmacological response mechanisms ofadapalene therapeutics. Topical 0.1% adapalene monotherapy was effective and safe, with significant evidence-based moleculardermatopharmacological efficacy.